Register Login

All Posts

New Statistics on Hemophilia Prevalence

Thanks to Elaine Benoit, Precision BioLogic Inc., for the heads-up on this newly released hemophilia study revealing a higher prevalence than previously reported. Also, the life expectancy disadvantage data are striking. Researchers from McMaster University, North Carolina State University, Aix-Marseille University, and the University of Sheffield joined efforts to respond to a call to action […]
read more

Zontivity (vorapaxar)

I’m curious about how many of our participants monitor vorapaxar (Zontivity®, New American Therapeutics, Inc) antiplatelet therapy. Vorapaxar is the only protease-activated receptor-1 (PAR-1) antagonist that reduces thrombotic cardiovascular events in patients with a history of myocardial infarction or peripheral arterial disease, FDA-approved in 2014. Vorapaxar is used alongside dual antiplatelet therapy (aspirin and clopidogrel; aspirin and ticagrelor) […]
read more

Factor Inhibitors: The SIPPET Study

Here is a short free full text article describing the outcomes of the 2010–17 Survey of Inhibitors in Plasma-Product Exposed Toddlers (SIPPET) study. The study compares inhibitor incidence arising from rFVIII (recombinant) concentrate compared to pdFVIII (plasma-derived) concentrate. Further, in an important addition to hemophilia therapy protocol, SIPPET also compares inhibitor incidence in hemophilic F8 […]
read more